The advent of immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 has transformed the therapeutic landscape of advanced non-small cell lung cancer (NSCLC), and recent clinical trials have extended their application to resectable disease. Mult... ...

请注册登录后继续浏览